Catalysts

Catalysts — What Can Move the Stock

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The next six months hinge almost entirely on one print: the H1 FY26 interim results around 22 September 2026, with a meaningful tell from the mid-July trading update beforehand. That sequence is where the market finds out whether organic growth holds 12%+ now that Hypothesis is fully wrapped and TRC is in the comp — the single number that resolves the "growth bought vs earned" debate keeping the EV/EBITDA at a non-existent premium to Accenture. The AGM (late June) carries unusual weight as the first remuneration vote under the Main Market regime, with three explicit UKCG opt-outs on the ballot. Outside those, the calendar is medium-thin: the $15.9m secondary placing closed two days ago is now in the rear-view; the death cross on 2026-03-05 is reassertion-of-trend territory; and FTSE 250 inclusion — repeatedly cited by management as the medium-term anchor — is mathematically out of reach in any 2026 review at the current ~$497m cap.

Ranked Catalyst Timeline

Date windows beyond 22 September 2026 are estimated from prior-year cadence (H1 25 trading update was 14 Jul 2025; H1 25 interim results 22 Sep 2025; FY24 AGM 24 Jun 2025). The company has not published a formal 2026 financial calendar to RNS.

Impact Matrix — Which Catalysts Resolve the Debate

The matrix is unusually concentrated: of six items, only two — the September interim and the AGM — actually resolve the underwriting debate cleanly. The other four either pre-tell September (the July update) or add side-information that reinforces a thesis already in motion (TRC true-up, insider dealing, next deal). A PM who can only follow one event should follow the September print.

Next 90 Days

The next 90 days run to ~30 July 2026. Four items inside that window:

• ~25 May 2026 — Paper Annual Report distribution. Substance is already on the FCA NSM; this is a low-impact administrative date but worth scanning for any RemCo policy changes (clawback adoption would upgrade governance grade) and confirmation of the FY25 contingent consideration true-up methodology. PM matter: only if disclosures contradict the digital AR.
• ~24 June 2026 — AGM. First remuneration vote under the Main Market regime. ISS/Glass Lewis recommendations typically publish 2-3 weeks before the meeting — that is the actionable read. AGM-day RNS often includes a short trading statement; that statement, not the votes, is the price-mover. PM matter: a protest vote >=20% on remuneration is a structural cap on multiple expansion; "in line with expectations" trading colour is mildly positive.
• ~26 June 2026 — FTSE UK Index June review effective. ELIX is well below the FTSE 250 threshold and will not be promoted; this matters only because management has made FTSE 250 inclusion a stated medium-term ambition. The June review is the first opportunity for the market to mark the timeline as "later than implied." PM matter: low — unless mgmt repeats the ambition with new specificity at AGM.
• ~14 July 2026 — H1 FY26 trading update. This is the main 90-day event. Watch the language vs the 14 Jul 2025 update ("continued growth, maintaining track record of profitable growth") and any quantitative colour on organic vs inorganic split. PM matter: the highest-information signal in the next 90 days because it pre-tells the September interim that resolves the central debate.

The September interim falls just outside the 90-day window (day 144). The 90-day calendar is therefore positioning-only; the underwriting decision is made in late September.

What Would Change the View

The investment debate over the next six months will be settled by three observable signals, in this order. First, the H1 FY26 organic growth print on or around 22 September 2026 — anything below 10% confirms the bear's roll-up critique and forces a multiple reset to statutory P/E; anything at 12% or above with margin holding 28%+ vindicates the bull case and rerates the stock toward broker consensus $14.30. Second, the trajectory of FCF after acquisitions and net debt — a positive H1 FCF-after-acquisitions number with net debt below $39.7m would retire the "self-funded compounder is dead" narrative the bear leans on; a deteriorating reading widens the gap between adjusted and statutory metrics that the market is currently ignoring. Third, founder insider direction — Newton stepping up open-market buying (versus continued slow selling) at any price would be the single highest-conviction insider signal in the file and would close the governance discount. None of the other items on the calendar — AGM, FTSE review, paper AR, next bolt-on — change the underwriting independent of these three. The thesis-changers are concentrated, well-dated, and observable; the calendar is otherwise medium-thin.